A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
UCL and Photobiotics announce partnership to tackle gastric cancer
18 October 2013
UCL, Photobiotics pursue new approach to gastric cancer
A new collaboration between University College London (UCL) and PhotoBiotics, a targeted oncology company spun out from Imperial College London in the UK, is looking to develop a multifunctional agent for use in both the diagnosis and treatment of gastric cancer.